Abstract: Neuroblastoma (NB) is the most common extra-cranial solid tumor in children. It has obvious heterogeneity and unique biological features. High-risk NB is recognized as a "cold tumor" in immunity. It has multidimensional immune evasion strategies. Based on these immune evasion strategies, researchers have performed a series of immunotherapy researches. Although, GD2 mono-antibodies based treatment has been included in the multi-modal treatment around the world, the 5-year survival rate of high-risk NB is still less than 50%. Immunotherapy studies targeting various effector molecules in high-risk NB cells and their immune microenvironment are being explored. These studies are expected to bring new hope to patients with high-risk NB. This article reviews the immunotherapy methods and the immunotherapy strategies in the research of high-risk NB patients.